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ABSTRACT 
IN VIVO STUDY OF THE EFFECTS OF DANAZOL ON 
CYTOPLASMIC RECEPTORS IN THE FEMALE RAT 
Deborah 
Morehead State 
Director of Thesis: 
The in vivo effects of the synthetic antigonado-
tropin, danazol, on cytosol receptor binding in three 
groups of Sprague-Dawley rats were studied. Percent 
change in specific binding of estrogen, progesterone, 
dihydrotestosterone and corticosterone binding in 
uterine, mammarian, adrenal, hypothalamic and ovarian 
tissues was investigated. To evaluate specific binding, 
incubations of tissue cytosols with a 1O0-fold excess of 
'cold' competitor was subtracted from the total binding 
of each incubate, and a hydroxylapatite micromethod 
assay was used to extract the steroid. 
Long term, low dose (4 mg/kg/14 days) danazol 
therapy in adult female rats resulted in a non-
significant decrease in all receptors compared to intact 
rats. Significant differences in estrogen receptor 
binding were noted (42% reduction), When ovariectomized 
rats received a continuation of danazol, a 45% reduction 
in estrogen binding occurred. Other steroid binding 
ii 
concentrations were unaffected by ovariectomy. Mammary 
tissue was not significantly changed in its ability to 
bind steroid receptors. 
A short term, higher dose (8 mg/kg/3 days) 
danazol therapy in pre-puberal female rats resulted in a 
non-significant decrease in binding of estrogen, 
progesterone and dihydrotestosterone in the uterus. In 
pooled adrenals and hypothalami, all but one receptor 
group decreased in specific receptor binding. The only 
increase was in estrogen binding in pooled adrenals. 
In addition, either antigonadotropic and/or androgenic 
effects of danazol were seen in relation to organ 
weights from both 
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INTRODUCTION 
The binding of steroid hormones to the cytoplasmic 
protein receptor of target cells initiates a series of 
reactions leading to specific protein synthesis. Studies 
of the mechanism of action of steroid hormones is 
essentially the study of protein receptor molecules and 
the behavior of a steroid-receptor complex in activating 
enzyme synthesis (O'Malley and Means, 1974). Such 
receptor molecules have been found to be highly specific 
for a given hormone and are found in significant amounts 
only in target cells. 
Early attempts to describe the molecular inter-
actions of steroids with cell components were unsuccessful 
because physiological amounts of hormones could not be 
detected with the techniques then available. An important 
factor in establishing the current understanding of the 
mechanism of action of steroid hormones was the synthesis 
of isotopically labeled compounds. These provided the 
first molecular probes to discern the sequence of events 
that occur following the interaction of a steroid hormone 
with a target cell. In 1960, Jensen and Jacobson injected 
3H-estradiol of high radiospecific activity into rats and 
determined that the target organs, uterus and vagina, 
retained the label much longer than non-target tissues. 
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Since the non-target tissues incorporated the labelled 
steroid and then quickly lost it, this indicated there 
was no permeability barrier to the entry of .estradiol 
into cells. Passage through the plasma membrane by the 
hydrophobic steroid was suggested to be by .diffusion. 
The retention of estradiol in the uterus for at least 
2 
six hours suggested that it must be bound by .these target 
cells and detained from leaving the cell (Jensen and 
Jacobson, 1962). 
Fractionation of uteri from rats previously. 
injected with 3H-estradiol showed that binding was 
stereospecific and that the label could be released aft.er 
treatment with proteases. This suggested that the 
steroid was bound to a protein (Notebloom and Gorski, 
1955). A clear demonstration that hormonally responsive 
tissues contained a particular macromolecule associating 
with the labeled ligand was reported by Toft and Gorksi 
(1966). These workers used sucrose gradient centrifuga-
tion to show that 3H-estradiol associated with a cyto-
plasmic protein in the rat uterus having a sedimentation 
velocity of 8-9 Svedberg units (S). This peak was 
maximal within twenty .minutes and could be blocked by. 
adding a competing estrogenic molecule such as 
diethylstilbesterol. Presumably .this inhibition was 
through competition of the same binding site with 3H-
estradiol (Toft and Gorski, 1966). 
I A smaller, 5S 3H-estradiol-protein complex was 
I 
extracted from uterine nuclei (Jensen, et al., 1967). I --
This complex which showed maximum binding after one 
hour was rkcovered from isolated nuclei to which 3H-
estradiol ias added in the presence of uterine cytoplasm 
I (Jensen, et al., 1968). No nuclear uptake of 3H-
estradiol1ccurred in isolated nuclei in the absence of 
uterine cyJosol. Furthermore, the amount of radio-
activity iJ uterine cytosol decreased while the nuclear 
I hormone concentration increased. This translocation of 
I 
' 
' the steroid into the nucleus was shown to be temperature 
I 
dependant ~Jensen, et al., 1968). I --
The interaction of the steroid-nuclear receptor 
I 
complex with chromatin was elucidated by O'Malley's lab 
! 
I in 1971 (Spelsberg, et al., 1971). Using the effect of 
I progesterone on the chick oviduct, they demonstrated that 
3 
I the progesterone-receptor complex (PgR) bound to both non-
histone acJdic proteins and DNA. This high affinity 
binding by the PgR complex acts to relieve the constraints 
at specific regions on the DNA, leading to the transcrip-
' 
tion of spJcific messenger RNA and subsequent protein 
synthesis.j Although an increase in the synthesis of a 
specific p otein may be affected by changes in the 
cytoplasm, it is thought that an increase in the rate of 
4 
transcription of DNA is the major cause of the increase in 
the number of mRNA molecules, which is responsible for 
the increale in protein concentration (Roth and Grunfeld, 
1981). 
The experiments primarily from the labs of Jensen 
and Gorskil have led to a postulate of a two step model 
I for the interaction of estradiol with its target cells in 
I the rat uterus. The basic tenets of this model seem to 
I 
hold true for all steroid hormone interactions. Figure 1 
illustrate! the model as developed by Jensen and DeSombre 
I 
(1973) andlupdated by Wittliff (1974). Basically, 
estradiol nters the uterine cell by diffusion where it 
binds to aA estrogen receptor protein forming the 
estradiol-Jeceptor complex (E2R ). This complex I C 
undergoes a temperature dependant transformation to a new 
I 
species called E2Rc'• which has the capacity to translocate 
into the nJcleus and where it is now called E2Rn. The 
E2Rn binds to specific chromatin acceptor sites where 
activation of RNA polymerase occurs-. New mRNA is 
transcribed with subsequent protein synthesis and 
I 
eventual cellular growth and division. 
' l I 
Althlugh the target cell contains the biologic 
capacity to associate with steroid hormone, this property 
does not oJligate the cell to respond in an appropriate 
manner. TJis is e~ident in cancer cells. If cancerous 
5 
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Proposed Ste2s 
1. 
R 1. Steroid Uptake C 
2. E2Rc 2. Cytoplasmic Binding 
I 3. Transformation 
3. ER I 2 C 4. Trans location 
5. Nuclear Binding 
6. Transcription 
7. Translation 
-6 .--~ 7. 
RNA RNA 
l 
E2 = Estradiol (Steroid Hormone) 
R = Cytoplasmic Binding Protein (Receptor 
C 
E2Rc = Estradiol-Receptor Complex (Cytoplasmic) 
E2Rc'= Estradiol-Receptor Complex (Nuclear) 
Proposed Steroid Hormone - Target Cell Interaction 
(Jensen and DeSombre, 1973; Wittliff, 1974). 
Figure 1 
Step 
tissue is dependent on steroid hormone for growth and 
survival, steroid hormone receptors will be present in 
sufficient quantity to propagate the cancerous cells. If 
however, an interruption in the intracellular events can 
be accomplished, the cancerous cells will die. Therefore 
any method to inhibit estrogen binding in the cytoplasm of 
estrogen dependent tumor cells, should reduce the tumor. 
Huggins stated "the quality of hormone dependence 
resides in the tumor cells, whereas their growth is 
determined by the host's endocrine status. The cure of 
cancer after deprival of the dependent hormone results 
from the death of the cancer cell, whereas normal cells 
may shrivel but survive" (Huggins, 1979). 
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Erdos reported that uterine cytosol contained two 
types of estradiol binding sites (Erdos, et al., 1970). 
Binding to type A sites occurs at low estrogen concen-
tration. The affinity is high, available binding sites 
are limited, and the complex formed is slowly reversible. 
Binding to type B sites occurs at higher estrogen concen-
trations where the affinity is low. In type B binding, 
the number of available binding sites is high and the 
complex formed is rapidly reversible (Erdos, et al., 1970). 
Hydroxylapatite, an inert and insoluble compound, has the 
ability to measure the concentration of estrogen-bound 
type A sites (Pavlik and Coulson, 1976). High affinity 
7 
binding, specific for cytoplasmic steroid receptors is 
reduced by non-steroidal competitors or 'cold', unlabeled 
hormone. In the presence of a 100-fold excess of 
unlabeled hormone, a percentage of binding is abolished 
indicating binding was saturable. This is a major 
criterion of receptor specificity. Thus specific binding 
of hormone receptor complexes can be determined by 
subtracting the non-specific binding from the total 
binding concentration. 
In America and Europe, mammary cancer has the 
highest rate of incidence of any malignant tumor of either 
sex. Women are the most susceptible with greater than 
99% of all mammary carcinomas. The incidence has remained 
stable even with women abandoning breast feeding and 
extensively using long-term steroids such as oral 
contraceptives (Huggins, 1979). Since normal breast 
tissue contains specific cytoplasmic binding sites for 
estrogens, progestogens, glucocorticoids and androgens, 
the usefulness of receptor studies for treatment of 
mammary cancer is being used as the basis for clinical 
trials with potential drug therapies. 
Historically, Beatson made the first observation in 
1896 that advanced mammary cancer could be induced to 
regress with surgical removal of both ovaries (Beatson, 
1896). Subsequently, numerous ablative procedures were 
performed including adrenalectomy and hypophysectomy. 
Urinary steroid levels were used at that time as an 
indicator of hormone levels and responsiveness to 
treatment. Radiation therapy was later used for 
endocrine ablation. Synthetic steroids were investigated 
as potential treatment since problems arose with the need 
for life-long hormone replacement in ablative therapy. 
The use of aromatic carcinogens in albino rats has 
altered the course of research on breast cancer. The 
Sprague-Dawley rat which easily develops mammary acinar 
cancer with exposure to cancer-inducing drugs such as 
7, 12-dimethylbenzanthrene (DMBA) has been used by 
researchers such as Huggins in breast cancer research. 
Many_ rat mammary cancers are completely hormone dependent 
and thus reverse with hormone therapy. In human breast 
cancer, the relationship between estrogen-binding 
capacity of the tumor and the patients' response to 
therapy is shown in Tables 1 and 2. Table 1 is a list of 
investigators compiled by Wittliff showing response to 
therapy (Wittliff, 1974). From the total number of 
patients, it can be stated that of those patients with 
tumors containing estrogen receptors, 78% exhibited 
objective remission following additive or ablative 
hormone therapy. Only six percent of patients with 
tumors lacking estrogen receptors showed any response 
with hormone therapy. 
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TABLE 1 
RELATIONSHIP BETWEEN ESTROGEN-BINDING CAPACITY OF BREAST 
TUMORS AND PATIENTS' RESPONSE TO THERAPY 
Investigators 
Jensen, et al. 
Maass, et al. 
Leung, et al. 
Engelsman, et al. 
Savlov, et al. 
Totals 
Number of patients exhibiting objective remission 
following additive or ablative hormone therapy 
Tumors containing 
estrogen receptors 
10/16 
6/7 
12/12 
14/17 
.2/4 
44/56 
Tumors lacking 
estrogen receptors 
1/29 
0/14 
2/10 
2/20 
0/7 
5/80 
(Wittliff, 1974) 
TABLE 2 
RELATIONSHIP BETWEEN ESTROGEN-BINDING CAPACITY OF 
BREAST TUMORS AND PATIENTS' RESPONSE TO THERAPY 
ER (fm/mg) Response 
3 4/47 = 8 % 
3-10 11/24 = 45% 
11-100 15/41 = 36% 
100 22/36 = 61% 
ER = estrogen receptor 
fm = femptomoles (10-15 ,moles) per mg protein 
PgR+ = progesterone receptor complex, positive 
(McGuire, 
% PgR+ 
10 
30 
50 
80 
1975) 
f-' 
0 
11 
Table 2 represents work by McGuire basing response 
rate on ER concentration (McGuire, 1975), To be 
considered ER positive, a tumor must have a concentration 
of equal to or greater than 7 femptomoles/milligram 
(fm/mg) cytosol protein. ER negative tumors contain less 
than 3 fm/mg cytosol protein. Table 2 shows that the 
overall response rate increases with the increasing ER 
concentration. Those tumors containing more ER complex 
also have a higher percent of PgR+ concentration. 
Perhaps the progesterone receptor which is thought to be 
inducible by the action of the ER complex on genomic 
sites would be a more appropriate indicator of response 
to endocrine manipulation (McGuire, 1975). 
Synthetic steroids are being used as endocrine 
therapy for numerous carcinomas based on receptor 
concentrations. One synthetic steroid being considered 
for treatment of br~ast carcinoma is Danocrine, the brand 
of danazol released in 1976 by the Sterling-Winthrop 
Research Institute Laboratory. Figure 2 shows the chemical 
structure of danazol as well as other biologically 
important steroids for comparison of structural 
similarities and differences. 
Danazol is a heterocyclic steroid related chemically 
to 17a,- ethinyl testosterone. Dmowski reported danazol to 
be antigonadotropic, antiestrogenic, antiprogestational 
Cholesterol 
0 
Progesterone 0 
Cortisol 
OH 
0 
Testosterone 
.... 0 
Danazol 
OH 
HO 
l 7S - Estradiol 
Comparison of Danazol With 
Some Biologically Important Steroids 
Figure 2 
C= CH 
I 
I 
12 
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and to have mild androgenic activity (Dmowski, 1979), 
The antigonadotropic properties of danazol were shown by 
the lowering of plasma follicle stimulating hormone (FSH) 
and luteotropic hormone (LIi) levels through the 
inhibition of hypothalamic LH releasing hormone secretion 
(Dmowski, 1979), Dmowski further stated that danazol at 
low dosage (4 mg/kg body weight) produced antigonado-
tropic effects while at high dosage (12 mg/kg body 
weight) an androgenic effect was seen. The marked 
separation of pituitary gonadotropin inhibitory activity 
from overt hormone activity makes danazol unique and 
available for more clinical use. 
I~ reviewing danazol's mode of action, Jenkin 
concluded that danazol may have antigonadotropic effects 
and steroid enzyme inhibitory effects but neither of 
these effects were sufficient to account for the complete 
mechanism of action (Jenkin, 1980). Danazol's effect on 
reported inhibition of cytoplasmic binding of hormone 
receptors warrants further consideration for its possible 
use in treatment of mammary carcinoma (Musich, et al,, 
1981) (Cook and Gibb, 1980). 
Whereas anti-estrogens, usually non-steroids, block 
the uptake of estrogen in target tissue by binding to 
the estrogen receptor, danazol as a mild androgen was 
shown by some researchers to bind to the androgen, 
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glucocorticoid and progesterone receptors, but not to the 
estrogen receptor (Barbieri, et al., 1979). Based on this 
evidence and the fact that danazol is derived from 17a-
ethinyl testosterone, danazol should be considered non 
estrogenic and non anti-estrogenic. Cook and Gibb 
described danazol as a possible competitive inhibitor of 
estradiol binding by competing with 3H-labeled estradiol 
for uterine receptors (Cook and Gibb, 1980). However 
patients were administered up to an 800 mg daily oral 
dosage of danazol in these studies. 
In vivo receptor studies of danazol binding have 
been conducted by Barbieri, et al. (1981), Musich, et al. 
(1981), Chamness, et al. (1980), and Wood, et al. 
(1975). In studies by Musich, et al., after short-term 
danazol administration a small but signi-ficant increase 
in uterine cytosol estradiol receptors was noted. Long-
term danazol administration showed a marked decrease in 
uterine estradiol receptor binding. The uterotropism 
of danazol may have been due to actual receptor 
modification and nuclear receptor studies may elucidate 
this possibility (Musich, et al., 1981). 
Danazol has been approved by the Food and Drug 
Administration for treatment of endometriosis and 
fibrocystic breast disease. Clinical trials using 
danazol for treatment of breast carcinoma were based on 
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convincing studies by Peters, et al. (1979). In 59 DMBA-
treated female rats, 75% developed mammary cancer. Of 
those that were then treated with danazol (100 or 400 mg/ 
kg/day) 66% showed tumor regression and 36% showed complete 
regression. Of 50 rats injected with danazol (100 or 
400 mg/kg/day) only 14% developed tumors after DMBA 
administration, while 84% of the control rats developed 
mammary cancer. The results of this study indicate that 
in animals with established tumors, danazol was effective 
in altering tumor growth and that the results were not 
dose dependent (Peters, et al., 1979). 
--
Based on the review of literature and the need for 
more danazol-binding studies to be documented, two in 
vivo experiments were conducted studying the effects of 
two dosage levels of danazol on cytoplasmic receptors 
of estrogen, progesterone, J.dihydrotestosterone and 
glucocorticoids in uterine, mamm~rian, hypothalamic, and 
adrenal tissue. Although this research is done on non-
cancerous tissue, research will be beneficial in future 
study of female rat and human mammary carcinoma. 
MATERIALS AND METHODS 
Animal ·care 
Two experiments were performed on female Sprague-
Dawley (S/D) rats. The rats were housed in cool quarters 
under a regimen of ten hours darkness and fourteen hours 
of artificial lighting. They were allowed Purina Rat 
Chow and tap water ·act libitum. 
·Experiment I 
Twenty-four female S/D rats. were divided into two 
groups. The first group was given daily _intramuscular 
(IM) injections of danazol (4 mg/kg body _weight) 
suspended in Planters Peanut Oil. This treatment 
continued for fourteen days. The control group 
received daily IM injections of peanut oil only fqr 
fourteen days. On treatment day nine, bilateral 
ovariectomy was performed on eight of the twelve 
experimental and control rats, leaving four intact in 
each group. Surgery was performed under anesthesia 
using Sodium Nembutal (Abbot Laboratories), (4 mg/100 gm 
body weight)injected intraperitoneally (IP). Sodium 
Penicillin G 10 mg was injected IM into each post-. 
operative rat. The ovariectomized group received an IM 
injection of 100 micrograms of estradiol benzoate on 
treatment day twelve. 
16 
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Preparation of Tissue 
All animals were sacrificed on treatment day 
fourteen. Tissues for assay were immediately removed, 
trimmed of excess fat, weighed to the nearest milligram, 
dropped into an iced, acetone-CO2 pellet bath, blotted, 
and kept frozen at -20°C until assays were performed. 
Preparation of Cytosol 
All reagents used for preparation of cytosol are 
listed in Table 3. Cytosol fraction was prepared by the 
method derived by Heidemann and Wittliff for the Beckman 
"Airfuge" (Heidemann and Wittliff, 1979). All tissues 
were prepared in the same manner. The frozen minced 
tissue was homogenized in cold phosphate buffer (2.0 ml/ 
gm tissue) with a Ten Broeck glass-glass homogenizer. 
All preparations were kept on .i9e at all times. Using 
an Oxford adjustable sampler micropipetting system, 
0.175 ml of cytosol was added to pre-cooled cellulose 
nitrate tubes (Beckman Instruments, Inc.) and placed in 
the pre-cooled (4°C.) head of a fixed-angle rotor type 
A-100 Beckman Airfuge (Beckman Instruments, (Inc.) and 
centrifuged at 110,000 .x g (24 psi) for 10 minutes. 
The protein concentration of the supernatant was 
confirmed later by _a.modified Lowry method (Lowry, 
et al. , 1951) . 
--
Danazol 
Hormones 
Hydroxylapatite 
Suspension 
TABLE 3 
REAGENTS 
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Brandname Danocrine, gift of Sterling-
Winthrop Research Institute. 
3H-17S-estradiol, progesterone, 
dihydrotestosterone, corticosterone; 
dissolved initially in absolute 
alcohol then diluted with phosphate 
buffer (pH 7.4) to appropriate 
concentrations (New England Nuclear, 
Corp.). 
Diethylstibesterol, progesterone, 
dihydrotestosterone, corticosterone; 
dissolved initially in absolute 
alcohol then diluted to appropriate 
concentrations with phosphate buffer 
(pH 7.4) (Sigma Chemical, Co.). 
100 ml TP buffer plus 2.5 gm DNA-
grade Bio Gel HTP hydroxy~apatite 
(Bio-Rad), pH adjusted to- 7.2. 
Phosphate Buffer 5 mM sodium phosphate, pH- 7.4; 1 mM 
Reagent A 
Reagent B 
Reagent C 
Reagent D 
Scintiverse 
Tris Buffer 
Wash Buffer 
r™ 
monothioglycerol; 10% glycerol. 
2% Na2co3 in 0.1 N NaOH. 
0. 5% CaSO 4 • 5 H2o in 1% Na.or K tart rate. 
25 ml reagent A plus 0.5 ml reagent B 
(mixed fresh daily). 
1:1, Phenol Folin Reagent: distilled 
water (mixed fresh daily). 
Universal LSC Cocktail (Fisher 
Scientific, Co.). 
50 mM Tris, 10 mM KH2P04, H.7 .. 2·at 4°C. 
Phosphate Buffer, pH 7.4; plus 1% 
(V/V) Tween 80. 
Hydroxylapatite Micromethod 
All reagents used for the hydroxylapatite micro-
method are listed in Table 3. The Oxford adjustable 
micropipette system was used for all micropipetting. 
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From pooled centrifuged supernatant (cytosol fraction), 
0.05 ml aliquots were incubated in duplicate for four 
hours at 4°C in 0.45 ml polyethylene microtubes (Bio-Rad 
Laboratories) with 0.05 pmol (0.1 ml of 2 x 10-10 ) 3H-
labeled hormone in 0.1 ml phosphate buffer. A parallel 
tube contained a 100-fold excess of competing unlabeled 
hormone. After incubation, 0.06 ml of hydroxylapatite 
(HAP) suspension was added to each microtube. After 
vortex, further incubation for 30 minutes was completed 
with gentle vortex every ten minutes. The microtubes 
were then centrifuged for 30 seconds in a pre-cooled 
Adams-Sero Fuge centrifuge (Clay-Adams, Inc.) at 1000 x g. 
The pellets were washed twice with 0.2 ml wash buffer, 
with centrifugation and gentle aspiration after each 
wash. After the final wash, centrifugation and 
aspiration, the resulting pellet in the end of the 
microtube was cut off and dropped into a scintillation 
vial. Scintiverse I (Fisher Scientific, Co.) or Insta 
Gel (Packard) scintillation Cocktail (10 ml) was added to 
each vial and all vials were counted for radioactivity in 
a Packard Tri-carb liquid scintillation counter (Model 
300-C). This method is summarized in Figure 3. 
Sacrifice SID Rat 
+ 
Remove tissue, weigh, freeze 
+ 
Homogenize in P04 buffer (2 ml/gm tissue) 
+ 
Centrifuge 100,000 x g for 10 minutes 
+ 
Supernatant (cytosol fraction) 
+ 
Hydroxylapatite assay 
" 
a. Cytosol ( 0. 05 nil) 
plus 
b. Cytosol (0.05 ml) 
plus 
20 
0.10 ml 3H-compound 
(duplicate) 
Incubate 4 hrs., 4°C 
." 
0 .1 ml 3H-compound plus 
(lOOx excess) competitor 
Incubate 4 hrs., 4°C 
Add hydroxylapatite 0.06 ml 
Incubate 30 min., 4°C 
Vortex every 10 min. 
+ 
Wash 2 x, 0.2 ml 
Buffer - Tween 80 
+ 
Centrifuge 1000 x g., 30 sec. 
+ 
Cut tip off with pellet 
+ 
Count in Liquid Scintillation Counter 
Hydroxylapatite Micromethod 
Figure 3. 
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Assay of Protein 
All reagents used for the assay of protein are 
listed in Table 3. To 0.05 ml pooled supernatant cytosol 
placed in cellulose nitrate tubes was added 0,05 ml 10% 
trichloroacetic acid. After centrifugation in the Beckman 
Airfuge at 90,000 x g (20 psi) for five minutes, 0.10 ml 
3N NaOH was mixed with the precipitated proteins and 
allowed to sit for 10 minutes at room temperature. The 
remainder of the determination for protein follows the 
standard Lowry procedure (Lowry, et al., 1951). Bovine 
serum albumin (1 mg/ml) was the standard. After the 
appropriate reagents were added, absorbance was read on 
the Spectronic-70 (Bausch and Lomb) at 750 nm. Protein 
concentration was established and expressed in mg/ml 
cytosol. 
Experiment ·.rr 
Ten female S/D rats were divided into two groups. 
The first group was given daily IM injections of danazol 
(8 mg/kg body weight) suspended in Planters Peanut Oil. 
This treatment continued for three days. The control 
group was given daily ,IM injections of _peanut oil only, 
for three days. 
Preparation of tissue, cytosol, and the hydroxylapa-
tite microassay were identical to those of Experiment I. 
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Statistical Analysis 
Analysis of data was by means of the Student's t 
test. 
RESULTS 
Experiment I 
The effect of 4 mg/kg of danazol for 14 days can be 
seen in Table 4. Daily injections of danazol showed a 
highly significant reduction of uterine weight expressed 
either in absolute or relative weight terms in rats which 
had intact ovaries. Ovariectomized rats failed to show a 
further reduction in weight after danazol injections. 
The reduction in uterine weight after ovariectomy is also 
highly significant (P < • 01) . 
Table 5 indicates that danazol has an effect on 
reducing pooled adrenal weight in intact rats but shows 
no additive reduction in adrenal weight after ovariectomy. 
Rats receiving daily injection of danazol (4 mg/kg 
body weight) for nine days had mean ovarian weights of 
130 ± 12 at the time of ovariectomy, compared to rats 
receiving only the vehicle (154 ± 20) as indicated. in 
Table 6. This reduction in ovarian weight was highly 
significant (P < • 02) • 
The effects of danazol injections on steroid 
receptors in the uterus is shown in Table 7. Danazol 
treated rats show a non-significant decrease in all 
receptors compared to intact rats with estrogen receptors 
showing a 28% reduction. However, significant differences 
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TABLE 4 
EXPERIMENT I 
EFFECT OF DANAZOL ON ABSOLUTE AND RELATIVE UTERINE WEIGHT 
Treatment Absolute 
Intact Control (n = 4) 
Intact * Danazol (n = 4) 
Ovariectomized Control (n = 8) 
Ovariectomized * Danazol (n=8) 
*Danazol = 4 mg/kg/day for 14 days 
**Mean± Standard Deviation 
a P < • 02 compared to Intact Control 
b P < .01 compared to Intact Control 
686 
498 
498 
489 
Uterine Weight Relative Uterine Weight 
(mg) (mg/100 gm body weight) 
± 30** 224 ± 14 
± 50a 174 ± 16a 
± 85b 180 ± 28a 
± 100b 176 ± 31a 
TABLE 5 
EXPERIMENT I 
EFFECT OF DANAZOL ON ABSOLUTE AND RELATIVE POOLED ADRENAL WEIGHT 
Treatment 
Intact Control 
* Intact Danazol 
Ovariectomized Control 
* Ovariectomized Danazol 
Absolute Adrenal Weight 
(mg) 
70.3 
64.8 
57.3 
57.1 
** 
*Danazol = 4 kg/day for 14 days 
**Mean adrenal weight calculated from pooled ·adrenals 
Relative Adrenal Weight 
(mg/1OO gm body weight) 
22.8 
23.5 
22.6 
23.7 
TABLE 6 
EXPERIMENT I 
EFFECT OF DANAZOL ON ABSOLUTE OVARIAN WEIGHT 
Treatment 
Control (n = 8) 
* Danazol (n = 8) 
*Danazol = 4 mg/kg/day for nine days 
**Mean± Standard Deviation 
a P < .02 Compared to ovariectomized controls 
Absolute Ovarian Weight 
(mg) 
154 ± 20 ** 
130 ± 12a 
Tissue 
Uterus 
Mammary 
*Danazol 
TABLE 7 
EXPERIMENT I 
PERCENT CHANGE IN RECEPTOR BINDING OF 3H-STEROIDS 
AFTER DANAZOL INJECTIONS AND OVARIECTOMY 
Treatment E2 DHT PROG 
intact 100 100 100 
+danazol * 28 + ** 17 + 23 + 
ovarx .42 + a 10 + 25 + 
+danazol 45 + a 20 + 24 + 
intact 100 100 100 
+danazol 2+ 11 + 5+ 
ovarx 12 + 7+ 8+ 
+danazol 15 + 12 + 10 + 
injected at dose of 4 mg/kg/day for 14 days 
CORT 
100 
13 + 
4+ 
8+ 
100 
2+ 
3t 
10 + 
**Arrows refer to increase t or decrease+ in specific binding compared to intact 
control 
a Significant from controls at P< .05 
NJ 
...:J 
were seen for estrogen receptors when the rats were 
ovariectomized (42% reduction) and when these castrated 
rats received danazol (45% reduction). The ovariectomy 
failed to reduce significantly the concentration of the 
other steroid receptors. Mammary tissue was not 
significantly changed in its ability to bind steroid 
receptors. 
Binding data for hypothalamic tissue and adrenal 
glands were incomplete since they were analyzed from 
pooled tissues. However, they demonstrated the general 
trend toward reduction of receptor binding. 
·Experiment II 
Table 8 shows that there was a non-significant 
increase in uterine weights after injection of danazol 
(8 mg/kg/day for 3 days) in pre-puberal rats. Adrenal 
weights were not significantly changed from controls 
(Table 8). 
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Specific binding of estrogen was demonstrated by 
adding a 100-fold excess of DES which resulted in 
abolishing- 78% of total estrogen binding. A 100-fold 
excess of unlabeled progesterone abolished total 
progesterone binding by 84%. Likewise, a 100-fold 
excess of unlabeled DHT abolished 84% of _the radioactive 
counts of total DHT binding. 
TABLE 8 
EXPERIMENT II 
EFFECT OF DANAZOL ON ABSOLUTE AND RELATIVE UTERINE 
AND ADRENAL WEIGHTS OF PRE-PUBERAL RATS 
Tissue Treatment 
Uterine Control (n = 5) 
* Danazol (n=5) 
Control (n = 5) 
Adrenal 
* Danazol (n=5) 
*Danazol = 8 mg/kg/day for 3 days 
**Mean± Standard Deviation 
N.S. = Not significant from controls 
Absolute Weight 
(mg) 
220 ± 41 ** 
247 ± 52 (N. S. ) 
21.4 ± 3.6 
20.6 ± 2.4 (N.S.) 
Relative Weight 
(mg/100 gm body weight) 
201 ± 35 
222 ± 41 (N. S.) 
19.7 ± 3.3 
18.5 ± 1.4 (N. S. ) 
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In evaluation of the percent change of receptor 
binding, Table 9 shows that there is a non-significant 
reduction in the binding of estrogen, progesterone and 
dihydrotestosterone receptors in the uterus. Although 
danazol showed a 23% increase in estrogen receptor binding 
in pooled adrenals, DHT levels decreased 10% of controls. 
Estrogen and DHT receptor binding was decreased 8% and 
22%, respectively, in pooled hypothalamic tissue. 
TABLE 9 
EXPERIMENT II 
PERCENT CHANGE IN RECEPTOR BINDING OF 3H-STEROIDS 
AFTER DANAZOL* INJECTIONS 
Tissue Estrogen Dihydrotestosterone Progesterone 
Uterus (n = 5) 11, -1- ** (N. S. ) 2-1-(N.S.) 20-1-(N.S.) 
Adrenals 
(pooled) 23 t 10 -1-
Hypothalamus 
(pooled) 8 -1- 22 -1-
*Danazol = 8 mg/kg/day for 3 days 
**Arrows refer to increase tor decrease -1- in specific binding compared to 
controls as follows: Control - Danazol injected· x '100 
Control 
N.S. = Not significant from controls 
DISCUSSION 
Two in vivo experiments using female rats have been 
conducted. The possible effects of a dose-relationship 
of danazol and/or ovariectomy on four cytosol receptors 
in five tissues have been investigated in the rat 
utilizing the ~ydroxylapatite micromethod. Total binding 
was reduced by the non-specific binding using 100-fold 
excess of non-labeled hormone to obtain specific binding. 
In Experiment I, specific binding in intact rats 
treated, with danazol (4 mg/kg body weight) shows a non-
significant reduction in all receptor binding in uterine 
cytosol (see Table 7). The estrogen binding in rats 
receiving danazol shows a 28% reduction from controls. 
Progesterone was reduced 23%, DHT reduced 17%, and 
corticosterone reduced 13% after danazol injections. 
These findings agree with similar-studies done in the past 
several years. Barbieri found that danazol displaced DHT 
receptors in rat prostate, displaced progesterone in an 
estrogen-primed rat uterus, and that glucocorticoid 
receptors were displaced by danazol in rat liver cytosol 
(Barbieri and Ryan, 1981). In another study, Potts showed 
that intact rats, pre-treated with danazol, showed 
significant inhibition in the pituitary and hypothalamic 
uptake of 3H-labeled estradiol. (Potts, 1977). Musich, 
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using a long term danazol at a high dosage, as opposed to 
low dosage as used in this study, showed a decrease in E-R 
binding which may have been due to the dose or the 
duration of treatment (Musich, et al., 1981). From a 
different viewpoint, Jenkin reported that danazol 
decreases the stimulatory effect on basal circulating 
levels of estrogen and progesterone to the uterus thereby 
also directly effecting estrogen receptors in the tissue 
(Jenkin, 1980). Jenkin also stated that danazol competed 
with the uterine cytosol receptor for the estradiol and 
progesterone receptors. 
The effect of ovariectomy on receptor binding was 
only significant for estrogen receptors (see Table 7). 
The 42% reduction of estrogen binding in ovariectomized 
rats was reduced to 45% in rats that received danazol 
injections in addition to the ovariectomy. This agrees 
with studies by Bohnet, et al. (1981) who reported that 
danazol prevented a compensatory increase in LH and FSH 
after ovariectomy. Potts found that ovariectomized rats 
treated with danazol significantly inhibited pituitary 
and hypothalamic uptake and thus binding of 3H-labeled 
estradiol (Potts, 1977). These findings disagree with 
findings by Wood who dimissed the local action by danazol 
on estrogen receptors when a 1000-fold excess of danazol 
did not effect the 3H-estradiol binding to endometrial 
34 
cytosol (Wood, 1975). However, Wood's study was in vitro 
and many times in vivo and in vitro studies cannot be 
compared. 
Other steroid receptor binding was not significantly 
reduced in Experiment I. The 25% reduction in progesterone 
binding after ovariectomy was not significant, a finding 
that differs from a study by Peters who reported that in 
ovarian hypofunction, a decrease in estrogen production 
would produce less progesterone receptors and thus 
reduced progesterone binding (Peters, et al., 1977). 
Danazol ~njections failed to influence a change in 
progesterone receptors after ovariectomy. 
With respect to mammary tissue, these studies were 
investigated with the hope that some data reflecting the 
influence of danazol on mammary receptors would be 
enlightening. However, from the data presented in Table 7, 
mature female rats, either intact or ovariectomized, 
showed no significant change in the ability to bind 
steroid receptors. 
The effect of danazol on the reduction of uterine 
and ovarian weights at low dose (4 mg/kg), long term 
(14 days), danazol treatment is consistant with that 
reported by other investigators (Jenkin, 1980) (Dmowski, 
1971). This might be expected since the reported 
antigonadotropic effects of danazol (Dmowski, 1971) and 
35 
the direct effect of danazol on inhibiting steroidogenesis 
(Barbieri and Ryan, 1981) should lead to a reduction in 
uterine weight. Adrenal weight reduction is also 
consistent with Kitay's findings that estrogens have a 
stimulatory effect on the adrenal glands (Kitay, et al., 
1963), and the more recent discovery that adrenals 
possess an androgen receptor which when bound by 
androgens, lowers adrenal weights (Rifka, 1978). Potts 
also reported a decrease in adrenal weights after danazol 
treatment (Potts, 1974). 
After short term danazol administration at high 
dosage (8 mg/kg/3 days) as seen in Experiment II, it can 
be said that the weight data are fairly consistent with 
findings by Barbieri and Ryan (1981), Potts (1974) and 
Dmowski (1971). The increase in uterine weight of pre-
puberal rats may be termed a uterotropic effect of the 
high dose of danazol. This uterotropic effect may be 
explained by a possible anti-estrogen mode of action of 
danazol at high dosage similar to that reported by 
Musich, et al. (1981), involving progesterone receptor 
studies of tamoxifen, an anti-estrogen. Effects here 
could be explained by the anabolic action of the 
androgens on the uterus which danazol could also produce 
at this dosage. 
The results from Experiment II again show that in 
all cases but one, danazol produced a decrease in specific 
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binding of estrogen, progesterone and DHT in the uterus 
and hypothalamus (Table 9). Only in the adrenals of the 
pre-puberal rat did a 23% increase of estrogen binding 
take place, while at the same time, DHT binding decreased 
10%. 
The controversy over danazol's steroid binding to 
cytosol receptors remains but it has been seen that 
danazol has an effect on multiple classes of steroid 
receptors. Although discrepancies from established data 
have been noted, it should be remembered that in vivo 
receptor studies may reflect the indirect effects of 
danazol. Therefore it should not be surprising that 
inconsistant receptor data might be seen. Even with in 
vitro studies discrepancies have been reported (Chamness, 
et al., 1980). Another possibility for disagreement on 
receptor binding studies is that the metabolites of 
danazol are hormonally active and may play a part in 
receptor variability (Krey, 1981). These metabolites 
and their effect were not investigated. 
Since steroid receptors are thermolabile, unstable 
proteins, possible variable results may be due to 
incorrect sample storage or assay conditions such as 
keeping the sample cold enough to enhance binding activity. 
Another consideration is that many receptor sites may be 
nuclear binding sites, so that cytoplasmic sites alone may 
not be an accurate display _of the influence of danazol 
and/or ovariectomy on receptor binding. In any event, 
receptor studies are a molecular index of endocrine 
function and dependency in a cell and improvements in 
quantitation of receptor complexes continue to be vital 
to hormone research and clinical therapy. 
In summary, the results reported in this study 
have demonstrated the following with danazol injections 
of 4 mg/kg/body we_ight: 
1). A highly significant reduction of uterine 
weight in ovariectomized and intact rats. 
2). A highly significant reduction in uterine 
weight after ovariectomy. 
3). A reduction in pooled adrenal weight (intact 
rats), with no additive weight reduction 
after ovariectomy. 
4). A highly significant reduction in ovarian 
weights after nine days of danazol 
injections. 
5). A non-significant decrease in all uterine 
receptors of danazol treated rats compared 
to intact rats. 
6). A significant difference in ovariectomized 
rats for estrogen receptors. 
7). Ovariectomy failed to reduce the concen-
tration of other steroid receptors. 
8). Mammary tissue was not significantly changed 
in its ability to bind steroid receptors. 
9). A general trend toward reduction of receptor 
binding in hypothalamic and adrenal glands. 
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With danazol injections of 8 mg/kg body weight, 
the following results were demonstrated: 
1). A non-significant increase in uterine 
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weights but not adrenal weights from controls. 
2). Specific binding of estrogen, progesterone 
and dihydrotestosterone were decreased by 
'cold' steroids. 
3). A non-significant reduction in the binding of 
estrogen, progesterone and dihydrotestosterone 
receptors in the uterus. 
4). An increase in estrogen binding in pooled 
adrenals with a decrease in DHT levels. 
5). A decrease in estrogen and DHT receptor 
binding in pooled hypothalamic tissue. 
These results, though inconclusive, may contribute 
to a better understanding of the effects of danazol at 
the molecular level. The significance of this type of 
research might allow for a better utilization of 
clinically prescribed endocrine therapy. 
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